Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Mohsin Badat, a Clinical Training Research Fellow from the Higgs and Davies Groups has been awarded the ASH-BSH Abstract Achievement Award by the American Society of Haematology and the British Society of Haematology.

Headshot of Dr Mohsin Badat. © Created on Canva Pro Account

The award recognises the abstract titled ‘Base Editing Repairs the HbE Mutation Restoring the Production of Normal Globin Chains in Severe HbE/β-Thalassemia Patient Hematopoietic Stem Cells and Erythroid Cells’ which was submitted to the 63rd ASH Annual Meeting and Exposition.

The ASH-BSH Abstract Achievement Award is an annual award celebrating trainees with the highest scoring abstracts at the meeting, of which they are first or senior author.

'I'm very grateful to the American Society of Hematology and the British Society for Haematology for this generous joint award.' says Dr Badat. 'The stipend will allow me to travel to the American Society of Hematology's annual meeting this year in Atlanta, where I will have the opportunity to present our recent progress in developing a base editing cure for HbE/beta-thalassaemia to the wider international haematology community. I hope that through this we will be able to collaborate with others in the field to help bring our approach into the clinical arena.'

Dr Badat will present during the Oral and Poster Abstracts session taking place on the evening of Sunday the 12th December 2021. 

Many Congratulations to Dr Badat!

Similar stories

New bone marrow model offers scalable platform for next-generation drug discovery

Researchers at the MRC Weatherall Institute of Molecular Medicine have developed the first combined human bone and bone marrow organoid platform capable of modelling long-term blood and immune cell production in a fully human 3D system.